Perspectives on results from recent CVOTs in type 2 diabetes.

26 August 2017 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in to view the resources

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail

Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

Professor L. Ryden (Stockholm, SE)

Presentation thumbnail

Cardiovascular effects of GLP-1 receptor agonists.

Doctor J. Plutzky (Boston, US)

Presentation thumbnail

Results from the LEADER cardiovascular outcomes trial.

Professor N. Poulter (London, GB)

Presentation thumbnail

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Professor L. Ryden (Stockholm, SE) Professor N. Poulter (London, GB) Doctor J. Plutzky (Boston, US)

Access the full session

Session thumbnail

Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

The Event

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources